Dutch health technology firm Royal Philips has launched its advanced QuickClear mechanical thrombectomy system in the US market, after receiving 510(k) approval from the US FDA.
The mechanical thrombectomy device is a compact, single-use, all-in-one aspiration pump and catheter system, intended to remove blood clots from the vessels in peripheral arterial and venous systems.
Philips said that its QuickClear system has been designed as a simple-to-use device with easy setup, to reduce the procedure times, prevent the need for equipment or expensive accessories.
Philips image guided therapy devices senior vice president and general manager Chris Landon said: “This novel thrombectomy system is the latest addition to Philips’ market-leading portfolio for the diagnosis and treatment of peripheral vascular diseases. Its intuitive design simplifies the entire thrombectomy procedure workflow.
“By taking away the high initial capital expenditure costs associated with traditional mechanical thrombectomy systems, QuickClear can help bring cost-effective solutions to both the hospital and outpatient care settings.”
According to the company, the small footprint of the device allows it to be placed easily and conveniently on the patient bedside during the procedure. QuickClear system can be started and run at maximum aspiration power within seconds, with one touch of a button.
QuickClear provides consistent aspiration power during thrombectomy procedures
QuickClear is said to simplify the thrombectomy procedure workflow, by providing consistent aspiration power during the procedure, providing physicians with enhanced control and reduction in the procedure times.
The system has a range of catheters that include a large 10F aspiration catheter, which provides 59% additional aspiration volume compared to 8F aspiration catheters, said the company.
Tristar Centennial Medical Centre vascular surgery chief Bryan Fisher said: “QuickClear is a simple and easy to use mechanical thrombectomy system. The system is significantly smaller than other systems without compromising aspiration power.
“The convenience of the device really shines through with its single-use and lack of capital equipment. I am excited about the potential of this device and the impact it will have on my practice and the patients I treat.”
Philips is already developing a portfolio of peripheral vascular devices, which includes advanced interventional imaging systems, intravascular ultrasound (IVUS) catheters, peripheral atherectomy devices, and peripheral therapy devices including Philips Stellarex drug-coated balloon.
The company has recently acquired Intact Vascular, a privately held medical device company for $275m. The company develops Tack Endovascular System, a minimal-metal, dissection repair device that offers precision treatment of peripheral arterial dissections after balloon angioplasty.
